3SBIO News

Sansheng Pharmaceutical (01530.HK): Approval of ITP indications for children in Terbi Australia is expected to support continued income growth

太平洋證券Apr 12 00:00

Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

TipRanksApr 5 17:40

Sansheng Pharmaceutical (01530.HK): Rapid growth in business performance, strong sales performance in Turbie Australia and Mandy

國信證券Mar 28 07:51

Sansheng Pharmaceutical (01530.HK): 2023 results are in line with expectations, Terby Australia's revenue is growing rapidly

中金公司Mar 22 07:21

Commentary on the 2023 annual results announcement of Sansheng Pharmaceutical (1530.HK): The main business is stable and the repurchase of Zhiyuan shares shows confidence

東北證券Mar 21 00:00

Sansheng Pharmaceutical (1530.HK): Steady growth of main business and innovation pipeline waiting to blossom

太平洋證券Mar 21 00:00

Sansheng Pharmaceutical (1530.HK): Steady fundamentals of hair growth products Mandy and subsequent pipelines continue to grow

民生證券Mar 8 00:00

Sansheng Pharmaceutical (01530.HK) In-depth Report: Competitive Business and R&D Dual-Drive PHARMA Starts Again

東北證券Jan 15 00:00

Sansheng Pharmaceutical (1530.HK): Domestic biopharmaceutical leaders continue to promote diversified innovation layout

太平洋證券Jan 5 00:00

Sansheng Pharmaceutical (1530.HK) Immediate Review: Mandy continues to grow at a high rate and R&D of innovative drugs is progressing smoothly

國元國際Aug 29, 2023 00:00

Sansei Pharmaceutical (01530.HK): Revenue has achieved rapid growth, and the R&D pipeline has entered a harvest period

國信證券Aug 28, 2023 00:00

Sansei Pharmaceutical (01530.HK): 1H23 performance exceeded expectations, compared with rapid growth in Australian revenue

中金公司Aug 27, 2023 00:00

Sansei Pharmaceutical (1530.HK): The basic market is growing stronger than Australia and is actively promoting self-exemption

國金證券Aug 24, 2023 00:00

Sansheng Pharmaceutical (1530.HK): R&D pipelines advance smoothly and Mandy continues to grow at a high level

國元國際Mar 28, 2023 00:00

Changes in Hong Kong stocks | Sansheng Pharmaceutical rose nearly 4%, and Lyon raised its target price to HK$9.33

Gelonghui FinanceMar 27, 2023 14:07

Sansheng Pharmaceutical (01530.HK): The growth rate of hair health products is impressive, and the revenue of core varieties such as Mandy is 910 million yuan, up 46.5% year-on-year

興業證券Mar 26, 2023 00:00

Sansheng Pharmaceutical (01530.HK): Steady growth in performance, own pipelines and imported products are worth looking forward to

國信證券Mar 24, 2023 16:47

Big Bank Ratings | Lyon: Sansheng Pharmaceutical raised its target price to HK$9.33 to “outperform the market”

Gelonghui FinanceMar 23, 2023 12:28

Sansheng Pharmaceutical (01530.HK): Steady operation and rapid growth of hair health and CDMO business under the influence of the epidemic

國信證券Sep 12, 2022 00:00

Sansheng Pharmaceutical (01530.HK) 2022 Interim Report Review: Core Product Revenue Is Steady and Progressing, and CDMO Business Continues to Grow

興業證券Aug 29, 2022 00:00